GW Pharmaceuticals PLC- ADR
GW Pharma is set to release its Q4 earnings on Thursday, December 3 before market open. For this quarter, analysts expect the cannabinoid biopharmaceutical company to post revenues of $15.02 million and a loss of ($1.05) per share, compared to last quarter’s revenues of $13.55 million and losses of ($1.58) per share.
One highlight from this quarter includes the company’s positive results from a study regarding the combination of cannabinoids and schizophrenia medication. The study indicated that 88% of patients who took antipsychotic drugs in addition to GWPH’s cannabinoid drug reported an improvement in symptoms, compared to those taking the placebo. Another highlight was October’s data regarding Sativex, the company’s cannabinoid drug intended to treat cancer pain. Dr. Marie Fallon, principle investigator of the drug’s Phase 3 program, stated, “While the results overall have been disappointing, and not necessarily wholly consistent with clinical experience, nonetheless they suggest that Sativex may have a useful role in the treatment of certain subgroups of patients with advanced cancer pain who have exhausted opioid treatments.”
According to TipRanks’ statistics, out of the 3 analyst who have rated GWPH in the last 3 months, all 3 gave a Buy rating. The average 12-month price target for the stock is $141, marking a 66% upside from where shares last closed.
Avago Technologies Ltd
Avago, a semiconductor company, is set to release its Q4 2015 earnings on Wednesday, December 2 after market close. Analysts estimate revenues of $1.85 billion and earnings of $2.38 per share, compared to last quarter’s non-GAAP revenue of $1.75 billion and non-GAAP earnings of $2.24 per share.
Last week, the company received approval from the European antitrust regulators for its $37 billion merger with Broadcom, another semiconductor company, announced in May of 2015. On November 10, analyst Cody Acree from Drexel Hamilton weighed in on the merger, initiating a Buy rating and a price target of $156.00. The analyst believes that this merger will result in more products and faster growth. He states, “We are encouraged by the BRCM acquisition as there are many areas where product, customer, and application synergies should create opportunities for faster growth. The combination of the two strong engineering teams should create opportunities in areas neither company heavily participates in today.”
According to TipRanks’ statistics, out of the 8 analysts who have rated AVGO in the past 3 months, all 8 gave a Buy rating. The average 12-month price target for the stock is $162.71, marking a 25% upside from where shares last closed.
Ambarella is set to release its Q3 2016 earnings on Thursday, December 3 after market close. For this quarter, analyst estimate the video-compression chip developer will post revenues of $89.9 million and earnings of $0.86 per share, compared to last quarter’s revenues of $84.2 million and non-GAAP earnings of $0.88 per share.
This quarter, the company suffered from falling shares prices due to weak quarterly results from its main customer, GoPro. Following these developments, analyst Quinn Bolton from Needham and Company weighed in on the stock, reiterating a Hold rating with no price target. The analyst notes that GoPro’s 3Q15 results, disappointing guidance, and rising inventory levels will have a negative effect on AMBA. He states, “GoPro’s disappointing 3Q15 results and 4Q15 outlook, together with a substantial increase in GoPro inventory levels, lead us to believe GoPro will likely reduce order rates in F2H16 to clear inventory.” He continues, “Reiterate Hold, reflecting the magnitude of expected order cuts.”
According to TipRanks’ statistics, out of the 10 analysts who have rated Ambarella in the last 3 months, 5 gave a Buy rating while 5 remain on the sidelines. The average 12-month price target for the stock is $103.50, marking a 77% upside from where shares last closed.
Uniqure NV, a company that develops gene-therapies, is set to release its Q3 2015 earnings report on Monday, November 30 before market open. Analysts believe the company will post revenues of $2.96 million and a loss of ($0.66) per share, compared to last quarter’s revenues of $1.81 million and a loss of ($0.70) per share.
In September, the company released data regarding its Phase 1/11 trials for its gene therapy AMT-110, intended to treat Sanfilippo B syndrome, a brain degeneration disease. All 4 patients treated with the therapy indicated incremental cognitive development in a 12 month period. After the company’s investor day in October, analyst Joshua Schimmer of Piper Jaffray reiterated an Overweight rating with a price target of $40, citing the company’s success in San Filippo and other neuro diseases. Schimmer stated, “Appreciation of the relevance of the San Filippo B data and awareness of the company’s recent progress to become an integrated gene therapy platform play are very low. Following the recent biotech sell-off, QURE now has an EV of only $150M. We encourage investors to return to this story to see the progress the company is making targeting neuro diseases (as well as liver and heart), evolving vectors, developing synthetic promoters, and manufacturing; we suspect they will be impressed with the progress that has been made.”
According to TipRanks’ statistics, out of the 6 analysts who have rated Uniqure in the last 3 months, all 6 gave a Buy rating. The average 12-month price target for the stock is $42.50, marking an 89% upside from where shares last closed.